APLS FOR TREATING ARTHRITIS
One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.
1 . A therapeutic composition comprising an altered peptide ligand (APL) for treatment or inhibition of Rheumatoid Arthritis (RA) in patients in need thereof.
2 . The therapeutic composition of claim 1 , wherein the APL comprises the amino acid sequence LGPKGQTGEBGIAGAKGDQGPKGEBGPA (SEQ ID NO: 2).
3 . The therapeutic composition of claim 1 in injectable form.
4 . The therapeutic composition of claim 1 in oral form.
5 . The therapeutic composition of claim 1 in a dose range effective to treat or inhibit RA in patients in need thereof.
6 . The therapeutic composition of claim 5 wherein the dose range is from about 30 μg/day to about 1,000 μg/day.
7 . The therapeutic composition of claim 6 wherein the dose is about 30 μg/day.
8 . The therapeutic composition of claim 6 wherein the dose is about 300 μg/day.
9 . The therapeutic composition of claim 6 wherein the dose is about 1000 μg/day.
10 . The therapeutic composition of claim 1 , further comprising one or more compounds selected from carriers, solvents, excipients, protecting groups, other biologically active compounds, and prodrugs.
11 . A method of treating or inhibiting RA comprising administering the therapeutic composition of claim 1 .
12 . The method of claim 11 wherein administering is to be performed over a period of time.
13 . The method of claim 12 wherein administering comprises one or more administrations within one day.
14 . The method of claim 12 wherein administering comprises one or more administrations over a period of time including one or more days.
15 . The method of claim 11 , further comprising enhancing the potency of the therapeutic composition of claim 1 using carbohydrates.
16 . A method of making the therapeutic composition of claim 1 , including genetic or non-genetic procedures.
17 . A method of inducing a Th2-type cytokine secretion profile in a mammal, comprising administering a therapeutic amount of A12 analog peptide.
18 . A method generating functional T regulatory cells, the method comprising administering a therapeutic amount of APL A12 to a RA patient.